New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
08:26 EDTIARTIntegra LifeSciences new products should boost sales, margins, says Argus
Argus believes that new products in Integra's Extremities and Spinal portfolios should boost its sales and gross margins. The firm expects the company's margin to expand in 2014, and keeps a Buy rating on the stock.
News For IART From The Last 14 Days
Check below for free stories on IART the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
08:38 EDTIARTIntegra LifeSciences announces commercial release of Integra Freedom system
Subscribe for More Information
September 17, 2014
11:26 EDTIARTIntegra LifeSciences management to meet with Oppenheimer
Subscribe for More Information
07:27 EDTIARTIntegra LifeSciences price target raised to $68 from $59 at Piper Jaffray
Piper Jaffray raised its price target for shares of Integra LifeSciences to $68 saying meetings with the company's CEO increased its confidence in its Overweight rating. Piper thinks Integra's performance will improve in 2015 and expects the stock to significantly outperform over the next 12 months.
06:09 EDTIARTIntegra LifeSciences to acquire Medtronic instrumentation lines for $60M
Integra LifeSciences (IART) and Medtronic (MDT) announced an agreement in which Integra will acquire Medtronic's MicroFrance and Xomed manual ENT and laparoscopy instrumentation lines for approximately $60M in cash. Integra expects the transaction to close in Q4. Integra will acquire a portfolio of approximately 4,000 MicroFrance and Xomed manual ENT and laparoscopic surgical instruments, as well as the St. Aubin le Monial, France manufacturing facility. Sales from the products being acquired totaled approximately $30M, two-thirds of which were generated outside the U.S. Integra expects to record approximately $27M-$30M in revenue and approximately 10c of adjusted EPS in calendar 2015 from this acquisition. The earnings accretion should rise after the first year once certain sales transitions are complete. The company expects the acquisition to contribute less than $5M in revenue and be neutral to earnings in Q4. The transition and integration is expected to be completed by 2H15.
September 10, 2014
10:21 EDTIARTIntegra LifeSciences management to meet with Piper Jaffray
Meeting to be held in the Mid-Atlantic area on September 16 hosted by Piper Jaffray.
September 8, 2014
16:21 EDTIARTIntegra LifeSciences says FDA began inspection of Aņasco facility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use